Table 3.
|
|
|
|
|
|
p valueb |
||
---|---|---|---|---|---|---|---|---|
NRTI-treated patients at GRT with | C | AG | F | p valuea | B | C vs. B | AG vs. B | F vs. B |
Exp to ddI or TDF or ABC or d4T | 21 | 18 | 26 | 405 | ||||
Therapy duration,c weeks, median (IQR) | 68 (33–100) | 47 (33–74) | 67 (26–127) | 68 (40–104) | ||||
K65R prevalence, N (%) | 4 (19.0) | 0 (0.0) | 0 (0.0) | 0.03 | 17 (4.2) | 0.01 | ||
Exp to ddI or TDF or ABC, but no exp to d4T | 17 | 8 | 22 | 141 | ||||
Therapy duration,c weeks, median (IQR) | 57 (17–109) | 37 (23–51) | 27 (24–92) | 49 (26–78) | ||||
K65R prevalence, N (%) | 1 (5.9) | 0 (0.0) | 0 (0.0) | 6 (4.2) | ||||
Exp to d4T, but no exp to ddI or TDF or ABC | 2 | 3 | 3 | 28 | ||||
Therapy duration,c weeks, median (IQR) | 72 (44–100) | 42 (29–54) | 77 (54–104) | 73 (37–109) | ||||
K65R prevalence, N (%) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 1 (3.6) |
Differences in the prevalence of K65R among the three non-B subtypes were assessed by the Chi square test (2×3 table).
Differences in the prevalence of K65R between non-B subtypes and the B subtype were assessed by the Fisher exact test.
Therapy duration indicates the total weeks under ddI, TDF, d4T, or ABC treatment.
The prevalence of the K65R mutation was calculated in groups of patients treated with NRTI and with a similar median therapy duration at the moment of the genotypic resistance test. Only significant p values (p<0.05) are reported in the table.
ABC, abacavir; AG, CRF02_AG; d4T, stavudine; ddI, didanosine; Exp, experience; GRT, genotypic resistance test; NRTI, nucleoside reverse transcriptase inhibitors; TDF, tenofovir.